



ARO A BIOSURGERY QUARTERLY RESULTS WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'ARO A' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Thursday April 27, 2023 at 9 AM AEST**, to discuss the Company's March quarter results which will be released pre-market the same day.

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_urJgyOwPQ9GtXzr2VZOVfQ

Questions can be submitted prior to the webinar to shinsley@aroabio.com or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary ARO A ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 5.9 million ARO A products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, ARO A is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contacts

Sarah Tora
Corporate Communications Manager
sarah.tora@aroabio.com
+ 64 21 531 043